Edition:
United States

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

141.85USD
26 Apr 2019
Change (% chg)

$0.36 (+0.25%)
Prev Close
$141.49
Open
$142.08
Day's High
$142.20
Day's Low
$140.44
Volume
39,542
Avg. Vol
683,883
52-wk High
$197.00
52-wk Low
$125.84

Latest Key Developments (Source: Significant Developments)

Appaloosa Comments On ISS Qualified Recommendation
Monday, 15 Apr 2019 09:52am EDT 

April 15 (Reuters) - Appaloosa::APPALOOSA COMMENTS ON ISS QUALIFIED RECOMMENDATION.APPALOOSA - URGE ALLERGAN SHAREHOLDERS TO VOTE FOR OUR PROPOSAL TO SEPARATE THE CHAIRMAN AND CEO ROLES.APPALOOSA - ISS’S RECOMMENDATION TO FORESTALL SEPARATION OF ALLERGAN’S CHAIRMAN, CEO ROLES IS A "MISUNDERSTANDING" OF REASONS FOR "UNDERPERFORMANCE".  Full Article

Allergan Is Reviewing Health Canada Notice To Suspend Co's Licences For Biocell Breast Implants
Thursday, 4 Apr 2019 03:23pm EDT 

April 4 (Reuters) - Allergan plc ::ALLERGAN IS CURRENTLY REVIEWING APRIL 4 HEALTH CANADA NOTICE OF ITS INTENT TO SUSPEND CO'S LICENCES FOR BIOCELL BREAST IMPLANTS - SPOKESWOMAN.ALLERGAN INTENDS TO RESPOND WITHIN THE DEADLINE PROVIDED BY HEALTH CANADA - SPOKESWOMAN.  Full Article

Appaloosa Says Files Supplemental Presentation On Allergan
Thursday, 4 Apr 2019 03:09pm EDT 

April 4 (Reuters) - Appaloosa::APPALOOSA SAYS FILES SUPPLEMENTAL PRESENTATION ON ALLERGAN.  Full Article

Health Canada Says Intend To Suspend Allergan's Biocell Breast Implants Licences As A Precautionary Measure
Thursday, 4 Apr 2019 01:45pm EDT 

April 4 (Reuters) - Health Canada::INFORMATION UPDATE - HEALTH CANADA ADVISES ALLERGAN OF ITS INTENT TO SUSPEND ITS LICENCES FOR BIOCELL BREAST IMPLANTS AS A PRECAUTIONARY MEASURE.HEALTH CANADA - AS OF APRIL 4, BEEN NOTIFIED OF 28 CONFIRMED CANADIAN CASES OF BIA-ALCL, OF WHICH 24 (86%) INVOLVE ALLERGAN'S BIOCELL BREAST IMPLANT.HEALTH CANADA - REVIEWING INFORMATION ON SAFETY OF TEXTURED BREAST IMPLANTS, INCLUDES ANY NEW EVIDENCE PROVIDED BY ALLERGAN IN NEXT 15 CALENDAR DAYS.HEALTH CANADA - ENGAGING INTERNATIONALLY ON SAFETY OF BREAST IMPLANTS, INCLUDING RECENT MEETINGS WITH FRENCH REGULATOR AND FDA.HEALTH CANADA - IF SATISFACTORY RESPONSE IS NOT RECEIVED FROM ALLERGAN IN NEXT 15 CALENDAR DAYS, INTENTION TO SUSPEND BIOCELL MEDICAL DEVICE LICENCES.HEALTH CANADA - IN CONTACT WITH FRANCE ABOUT ITS DECISION TODAY TO SUSPEND SALE OF MACRO-TEXTURED BREAST IMPLANTS, POLYURETHANE-COATED BREAST IMPLANTS.HEALTH CANADA - ENTIRETY OF ITS SAFETY REVIEW OF BREAST IMPLANTS AND BIA-ALCL WILL BE AVAILABLE BY END OF APRIL.HEALTH CANADA SAYS STARTED A SECOND SAFETY REVIEW ON SYSTEMIC SYMPTOMS ASSOCIATED WITH BREAST IMPLANTS.HEALTH CANADA - RESULTS OF THE SECOND SAFETY REVIEW WILL BE MADE PUBLIC IN SUMMER 2019..  Full Article

Allergan Launches Juvéderm Volux - The Latest Evolution In Facial Filler Treatments
Thursday, 4 Apr 2019 09:00am EDT 

April 4 (Reuters) - Allergan plc ::ALLERGAN LAUNCHES JUVÉDERM® VOLUX - THE LATEST EVOLUTION IN FACIAL FILLER TREATMENTS FOR THOSE SEEKING A MORE DEFINED CHIN AND JAWLINE.  Full Article

Appaloosa Says Released Investor Presentation On Allergan
Monday, 25 Mar 2019 07:30am EDT 

March 25 (Reuters) - Allergan plc ::APPALOOSA STATEMENT REGARDING ALLERGAN PROXY FILING.APPALOOSA LP - STATEMENT IN RESPONSE TO ALLERGAN'S MARCH 22 PROXY FILING, INTENTION TO INSTALL INDEPENDENT CHAIRMAN AT NEXT CEO TRANSITION.APPALOOSA SAYS RELEASED INVESTOR PRESENTATION ON ALLERGAN.  Full Article

Allergan Says CEO Brenton Saunders' 2018 Total Compensation Was $6.6 Million
Friday, 22 Mar 2019 05:24pm EDT 

March 22 (Reuters) - Allergan plc ::ALLERGAN SAYS CEO BRENTON SAUNDERS' 2018 TOTAL COMPENSATION WAS $6.6 MILLION - SEC FILING.  Full Article

Allergan to Present New Data On Eye Implant Bimatoprost SR
Thursday, 14 Mar 2019 07:30am EDT 

March 14 (Reuters) - Allergan plc ::ALLERGAN TO PRESENT NEW DATA - "EXTENDED DURATION OF INTRAOCULAR PRESSURE (IOP) CONTROL WITH INTRACAMERAL BIMATOPROST SUSTAINED-RELEASE (SR) IMPLANT" -- HIGHLIGHTING CLINICAL ADVANCES AT THE AMERICAN GLAUCOMA SOCIETY ANNUAL MEETING.ALLERGAN PLC - US NDA SUBMISSION EXPECTED IN SECOND HALF OF 2019.  Full Article

Allergan Says FDA Accepts New Drug Application For Ubrogepant For The Acute Treatment Of Migraine
Monday, 11 Mar 2019 07:30am EDT 

March 11 (Reuters) - Allergan plc ::ALLERGAN ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR UBROGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE.ALLERGAN PLC - ALLERGAN CONTINUES TO EXPAND ITS LEADING MIGRAINE PORTFOLIO ACROSS SPECTRUM OF DISEASE FROM EPISODIC TO CHRONIC -.ALLERGAN PLC - 10-MONTH REVIEW PERIOD HAS BEEN ASSIGNED WITH PRESCRIPTION DRUG USER FEE ACT (PDUFA) IN Q4 OF 2019..ALLERGAN PLC - U.S. FDA HAS ACCEPTED COMPANY'S NEW DRUG APPLICATION (NDA) FOR UBROGEPANT FOR ACUTE TREATMENT OF MIGRAINE IN ADULTS.  Full Article

FDA Accepts SBLAS For Botox For Pediatric Patients With Upper And Lower Limb Spasticity
Thursday, 7 Mar 2019 08:00am EST 

March 7 (Reuters) - Allergan plc ::FDA ACCEPTS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATIONS (SBLAS) FOR BOTOX® (ONABOTULINUMTOXINA) FOR PEDIATRIC PATIENTS WITH UPPER AND LOWER LIMB SPASTICITY.ALLERGAN PLC - APPLICATIONS SEEK TO EXTEND USE OF BOTOX FOR PATIENTS 2 TO 17 YEARS OLD.ALLERGAN PLC - PEDIATRIC LOWER LIMB SPASTICITY INDICATION WILL UNDERGO A STANDARD 10-MONTH REVIEW WITH A PDUFA DATE EXPECTED IN Q4 OF 2019..ALLERGAN PLC - PEDIATRIC UPPER LIMB SPASTICITY INDICATION HAS BEEN DESIGNATED A 6-MONTH PRIORITY REVIEW WITH A PDUFA DATE EXPECTED IN Q2.  Full Article

Photo

Proxy firms back Allergan in fight against Appaloosa

Two leading shareholder advisory firms threw their support behind Allergan Plc's management by recommending that investors vote against billionaire investor David Tepper's proposal that the Botox maker immediately split the roles of chief executive officer and chairman.